Podcasts about chimeric

Authors Gloria Iacoboni and María Pérez Raya outline the management of a patient receiving Chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL). CAR T-cell therapy is effective in the treatment of patients with DLBCL, even those with high-grade disease. However, it has a unique safety profile, including cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and robust management of these events are important to maximize benefits. This vodcast audio is published open access in Oncology and Therapy as a vodcast article with visual elements and is fully citeable. You can access the original published vodcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00319-x. All conflicts of interest can be found online. This vodcast audio is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

In this episode of the Nephilim Death Squad, hosts David Lee Corbeau and Top Lobster dive deep into the ancient genetic mysteries of the Nephilim, hybrid creatures, and the cryptids of old. Joined by Brian from Demon Erasers, the conversation spans the historical and biblical evidence of chimeric beings, dwarfism, the deceptive power of telepathic communication, and the nature of cryptid encounters around military bases. They also touch on St. Christopher's possible dog-headed origins, the legacy of Esau, and the implications of current disclosure on UAP phenomena. Tune in for a captivating discussion that merges history, theology, and the paranormal.JOIN THE PATREON FOR AD FREE EPISODES BEFORE THEY DROP AND BECOME PART OF THE GROWING COMMUNITY OF DANGEROUS RTRDs ON TELEGRAM:https://www.patreon.com/NephilimDeathSquadFIND US ON SOCIAL MEDIA:NEPHILIM DEATH SQUAD:Nephilim Death Squad / SpreakerNephilim Death Squad / YouTubeNephilimDeathSquad / Rumble(@NephilimDSquad) / X(@nephilimdeathsquad) / Instagram(@nephilimdeathsquad) | TikTokTOPLOBSTA:(@TopLobsta) / X(@TopLobsta) / InstagramTopLobsta.com / MerchRAVEN: (@DavidLCorbo) / X(@ravenofnds) / InstagramWEBSITES:Nephilim Death Squad | MerchBecome a supporter of this podcast: https://www.spreaker.com/podcast/nephilim-death-squad--6389018/support.

Chimeric antigen receptor (CAR)-T cell therapy has made impressive advancements in treating patients with blood cancers, such as leukemia and lymphoma, for more than a decade now. In this episode, we traverse the challenges and innovations of cell immunotherapy and better understand the design behind these logic-gated, genetically engineered cytotoxic cells with Dr. Yvonne Chen, a leading expert in the field. Dr. Chen is an incredibly accomplished Professor of the MIMG and CBE departments at UCLA and currently leads a Phase 1 Clinical Trial (NCT04007029) using bispecific anti-CD19/anti-CD20 CAR-T cells to treat patients with B cell malignancies. For more information on Dr. Chen's research: http://yvchen.bol.ucla.edu/. Music: https://pixabay.com/music/id-112777/ Episode Team:Guests - Dr. Yvonne ChenHost - Brenda JiScript Writers - Brenda JiAudio - Daniel NguyenProducers - Artin Allahverdian, Sonali JoshiDirector - Vy Han, MD

Sabina Kaczanowska's research focus is to understand the role of the immune system in shaping the microenvironment of metastasis during cancer progression. Specifically, she is investigating how myeloid cells orchestrate the immunosuppressive program in the pre-metastatic niche and how we can apply this knowledge of myeloid biology to design new immunotherapeutic strategies for the treatment of solid tumors. She joined us on OsteoBites to discuss her recently published paper on Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.https://pubmed.ncbi.nlm.nih.gov/38134936/Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors. The NCI conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating feasibility and safety of administration in children and young adults with osteosarcoma and neuroblastoma. Patient samples were evaluated by multi-dimensional proteomic, transcriptomic, and epigenetic analyses. The data uncover mediators of CAR-T biology and correlates of expansion that could be utilized to advance immunotherapies for solid tumor patients.https://clinicaltrials.gov/study/NCT02107963Dr. Sabina Kaczanowska received her Ph.D. in Molecular Microbiology and Immunology from the University of Maryland, Baltimore for her dissertation work on T-cell immunotherapy at the UM Marlene and Stewart Greenebaum Comprehensive Cancer Center. She joined the Tumor Microenvironment and Metastasis Section of the Pediatric Oncology Branch at the National Cancer Institute as a postdoctoral fellow in 2017 with Dr. Rosandra Kaplan. Dr. Kaczanowska was appointed as a Staff Scientist in the Pediatric Oncology Branch in 2022 to continue her work evaluating the responses of solid tumor patients to immunotherapy and translating new immuno-oncology approaches into the clinic.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Detecting Genetically Engineered Viruses With Metagenomic Sequencing, published by Jeff Kaufman on June 27, 2024 on The Effective Altruism Forum. This represents work from several people at the NAO. Thanks especially to Dan Rice for implementing the duplicate junction detection, and to @Will Bradshaw and @mike_mclaren for editorial feedback. Summary If someone were to intentionally cause a stealth pandemic today, one of the ways they might do it is by modifying an existing virus. Over the past few months we've been working on building a computational pipeline that could flag evidence of this kind of genetic engineering, and we now have an initial pipeline working end to end. When given 35B read pairs of wastewater sequencing data it raises 14 alerts for manual review, 13 of which are quickly dismissible false positives and one is a known genetically engineered sequence derived from HIV. While it's hard to get a good estimate before actually going and doing it, our best guess is that if this system were deployed at the scale of approximately $1.5M/y it could detect something genetically engineered that shed like SARS-CoV-2 before 0.2% of people had been infected. System Design The core of the system is based on two observations: If someone has made substantial modifications to an existing virus then somewhere in the engineered genome there will be a series of bases that are a good match for the original genome followed by a series of bases that are a poor match for the original genome. We can look for sequencing reads that have this property and raise them for human review. Chimeric reads can occur as an artifact of sequencing, which can lead to false positives. The chance that you would see multiple chimeras involving exactly the same junction by chance, however, is relatively low. By requiring 2x coverage of the junction we can remove almost all false positives, at the cost of requiring approximately twice as much sequencing. Translating these observations into sufficiently performant code that does not trigger alerts on common sequencing artifacts has taken some work, but we now have this running. While it would be valuable to release our detector so that others can evaluate it or apply it to their own sequencing reads, knowing the details of how we have applied this algorithm could allow someone to engineer sequences that it would not be able to detect. While we would like to build a detection system that can't be more readily bypassed once you know how it works, we're unfortunately not there yet. Evaluation We have evaluated the system in two ways: by measuring its performance on simulated genetic engineered genomes and by applying it to a real-world dataset collected by a partner lab. Simulation We chose a selection of 35 viruses that Virus Host DB categorizes as human-infecting viruses, with special attention to respiratory viruses: Disease Virus Genome Length AIDS HIV 9,000 Chickenpox and Shingles Human alphaherpesvirus 3 100,000 Chikungunya Chikungunya virus 10,000 Common cold Human coronavirus 229E 30,000 Common cold Human coronavirus NL63 30,000 Common cold Human coronavirus OC43 30,000 Common cold Human rhinovirus NAT001 7,000 Common cold Rhinovirus A1 7,000 Common cold Rhinovirus B3 7,000 Conjunctivitis Human adenovirus 54 30,000 COVID-19 SARS-CoV-2 30,000 Ebola Ebola 20,000 Gastroenteritis Astrovirus MLB1 6,000 Influenza Influenza A Virus, H1N1 10,000 Influenza Influenza A Virus, H2N2 10,000 Influenza Influenza A Virus, H3N2 10,000 Influenza Influenza A Virus, H7N9 10,000 Influenza Influenza A Virus, H9N2 10,000 Influenza Influenza C Virus 10,000 Measles Measles morbillivirus 20,000 MERS MERS Virus 30,000 Metapneumovirus infection Human metapneumovirus 10,000 Mononucleosis Human herpesvirus 4 type 2 200,000 MPox Monkeypox virus 200,000 Mumps Mumps orthor...

We've talked a lot about the opportunities and possibilities of how regenerative therapies can work, so today I wanted to get into the nuts and bolts how it all works.In this episode, we'll be discussing:➡️ Inflammation and how it causes both functional repair and dysfunctional repair.➡️ Regenerative therapies for osteoarthritis, irritable bowel syndrome and colitis.➡️ How a small population of people immune to HIV may be the secret to completely curing it.➡️ Chimeric cells and their role in treating disease. ➡️ Why the medical field has one of the largest data pools for study, and how we can use AI to compile this data and accelerate therapies.And, of course, I kick off the episode associating the lessons I've learned as a pilot with lessons that can be learned in healthcare.  This is Piloting Health.Follow Dr. Bob Hariri on his platforms here:Web: www.pilotinghealth.comInstagram: https://www.instagram.com/drbobhariri/X: https://twitter.com/DrBobHaririTikTok: https://www.tiktok.com/@pilotinghealthLinkedIn: https://www.linkedin.com/in/drbobhariri/

Chimeric antigen receptor T cell (CAR-T) therapies targeting the CD19 antigen have been associated with high and durable response rates in patients with diffuse large B cell lymphoma (DLBCL). In this podcast, Dr. Foley and Dr. Kuruvilla discuss the case of a patient presenting with the ideal profile for CAR-T cell therapy referral whilst also determining the key attributes for eligibility from a clinician's perspective. Solutions for successful outpatient management include proper education, caregiver support, and early referral to ensure a timely infusion. In conclusion, outpatient administration of CAR-T cell therapy in patients with DLBCLs should be assessed on a case-by-case basis.   This podcast is adapted from a vodcast article published open access in Oncology and Therapy and is fully citeable. The vodcast article features the same audio, but is accompanied by slides and author video. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00272-9. All conflicts of interest can be found online. This podcast is intended for medical professionals.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.  

Michael Tees, MD, MPH, Colorado Blood Cancer Institute, Denver, CO Recorded on March 12, 2024 Michael Tees, MD, MPH Director, Lymphoma Program Lymphoma Executive Committee Member, Sarah Cannon Research Institute Associate Member, Colorado Blood Cancer Institute Denver, CO Join Dr. Michael Tees from the Colorado Blood Cancer Institute, as he discusses Chimeric antigen receptor (CAR) T-cell therapy in 2024. Dr. Tees provides an overview of immunotherapy and approved indications, how to discuss treatment options with your patients, what to consider when referring patients for CAR T-cell therapy, how to prepare patients, and educating patients and caregivers about toxicity management. He also provides insight into the limitations of CAR-T therapy, as well as future directions. Tune in to this informative episode today to learn more! This episode is supported by Bristol Myers Squibb, Johnson & Johnson|Legend Biotech, Kite, a Gilead Company, and Novartis Pharmaceuticals Corporation.

Snallygaster - a mythical creature from American folklore, often described as a winged, bird-like monster with a reptilian presence. Its origins lie in the rural regions of Maryland, where tales of this cryptid have been woven into the fabric of local legends. Discover more TERRIFYING podcasts at http://eeriecast.com/   Follow Carman Carrion!    https://www.facebook.com/carman.carrion.9/   https://www.instagram.com/carmancarrion/?hl=en   https://twitter.com/CarmanCarrion   Subscribe to Spotify! https://open.spotify.com/show/0uiX155WEJnN7QVRfo3aQY   Please Review Us on iTunes! https://podcasts.apple.com/us/podcast/freaky-folklore/id1550361184   Music and sound effects used in the Freaky Folklore Podcast have or may have been provided/created by:  CO.AG: https://www.youtube.com/channel/UCcavSftXHgxLBWwLDm_bNvA Myuu: https://www.youtube.com/channel/UCiSKnkKCKAQVxMUWpZQobuQ Jinglepunks: https://jinglepunks.com/ Epidemic Sound: https://www.epidemicsound.com/ Kevin MacLeod: http://incompetech.com/ Dark Music: https://soundcloud.com/darknessprevailspodcast Soundstripe: https://a Learn more about your ad choices. Visit podcastchoices.com/adchoices

3PMD Episode #346 Topics for “Wednesday” 6:30 P/T 0:00 intro 0:55 Will Smith Duane Martin rumors "The Gay Gatekeepers 8:37 Andre 3000 Flute album 15:49 Elon Musk ‘Neuralink' FDA approved 23:51 First ‘Chimeric' monkey created with embryonic stem cell 32:09 Man receives the first eye transplant & a new face 37:57 He's ‘feminine' & I'm ‘masculine' 48:52 Joe Rogan's new contract is going to break the bank!!! https://www.msn.com/en-us/health/other/thousands-of-people-are-reportedly-lining-up-to-have-a-portion-of-their-skull-removed-and-one-of-elon-musk-s-brain-chips-implanted/ar-AA1jxFpi?ocid=hpmsn&cvid=1ba08d8915144f62b3e9cfd44e2d3ead&ei=74 https://themessenger.com/tech/chimeric-monkey-created-with-embryonic-stem-cells-born-in-chinese-lab https://www.msn.com/en-us/health/health-news/man-receives-the-first-eye-transplant-plus-a-new-face-it-s-a-step-toward-one-day-restoring-sight/ar-AA1jF1aU?ocid=hpmsn&cvid=a5e656aadef64304a8abd7f1807c9f7e&ei=64 https://youtu.be/3HLnSD0drEE?si=KVwFzR6mty_xDH_i https://www.msn.com/en-us/money/companies/joe-rogan-holds-all-the-cards-as-his-spotify-podcasting-deal-is-set-to-expire/ar-AA1jtNkv?ocid=hpmsn&cvid=cfc9e50e745b41eba22191611a9f87e2&ei=55 --- Send in a voice message: https://podcasters.spotify.com/pod/show/schwebelroom/message

RobChrisRob returned from their away missions to Wish Woz Well, talk about OLED steamdecks, nintendo pushing forward a live action Zelda film, Neil Gaiman's Dead Boy Detectives coming to netflix, KeeperFX releasing an asset compatible codebase for Dungeon Keeper, Ghostubsters Frozen Empire getting a trailer, Cities Skylines 2 rendering shenangigans, the Supreme Courts totally important code of ethics, scientists creating chimeric monkeys, and the release of The Marvels- which currently was appreciated by 100% of the GIS hosts who saw it... that is to say 1 out of 3. Join our discord to talk along or the Subreddit where you will find all the links https://discord.gg/YZMTgpyhB https://www.reddit.com/r/TacoZone/

link below to help us in our time of need! https://givesendgo.com/GB6F9?utm_source=sharelink&utm_medium=copy_link&utm_campaign=GB6F9. Venmo - @Rodney-Smith-368. Cash app - $Rodsworth77 Epic Video done by Enoch from the Rundown of our Reality .. You Dont want to miss this One! please share this Episode! Links to Enoch's content below ⬇️https://youtube.com/@therundownofourrealit yhttps://www.bitchute.com/channel/5W3JeLw UJbPp/https://rumble.com/c/c-1213932 Podcasts New website! Link here ⁠https://www.mms.agavaa.com/⁠  index.phpMinistry - Bride Ministries InternationalCheck out my recommended church app! From Daniel Duval, Download it for free here: http://brideministries.app.link/ Please leave me a 5-star review on your favorite podcast app/ catcher, whichever Youse listen on. Or join by monthly donations on Support this podcast: https:// ⁠podcasters.spotify.com/pod/show/rodney_-jay/support⁠ - Music from Uppbeat:Free Music For YouTube Videos & Creators •UppbeatLicense code: PFREJYBLQKUZTMDH Support podcast: https://podcasters.spotify.com/pod/show/rodney-jay/support--- Send in a voice message: https://podcasters.spotify.com/pod/show/rodney-jay/message  Venmo - @Rodney-Smith-368 Cash app - $Rodsworth77 --- Send in a voice message: https://podcasters.spotify.com/pod/show/rodney-jay/message Support this podcast: https://podcasters.spotify.com/pod/show/rodney-jay/support

Daniel - The Chimeric Dream King October 22, 2023 Pastor Neal Pafford

Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the successful results of a new brain cancer (glioblastoma) treatment trial. The phase 1A trial achieved a 55% disease control rate (DCR) in patients treated with its CLTX CAR T solution, well above historical disease control rates. Under that trial two patients exceeded a survival period of 14 months, while three patients remained alive and in follow up. This is in direct comparison to survival expectations of around 7 months for patients after first line therapy. Data obtained from the dose escalation program has provided highly encouraging results, particularly with a number of participants considered very late stage cancer patients. Chimeric is now opened enrolment for the phase 1B stage of the trials. Articles:https://smallcaps.com.au/chimeric-therapeutics-positive-interim-data-cltx-car-t-brain-cancer-trial/https://smallcaps.com.au/chimeric-therapeutics-chm-0201-cell-study-treatments-acute-myeloid-leukaemia/https://smallcaps.com.au/chimeric-therapeutics-completes-further-dosing-brain-cancer-clinical-trial/https://smallcaps.com.au/imugene-worldwide-licence-cd19-cell-therapy-treat-relapsed-cancer-patients/ For more information on Chimeric Therapeutics:https://smallcaps.com.au/stocks/asx-chm/See omnystudio.com/listener for privacy information.

Featuring a slide presentation and related discussion from Dr Jeremy Abramson, including the following topics: Long-term follow-up data with Bruton tyrosine kinase (BTK) inhibitors as monotherapy for chronic lymphocytic leukemia (CLL): The CLL12 and SEQUOIA trials (0:00) Extended follow-up results with venetoclax combined with anti-CD20 antibodies or a BTK inhibitor for CLL: The CLL14, MURANO and GLOW trials (5:27) Primary analysis of the TRANSCEND CLL 004 trial evaluating lisocabtagene maraleucel for relapsed/refractory (R/R) CLL (12:40) Genomic evolution and resistance to pirtobrutinib in patients with covalent BTK inhibitor-pretreated CLL in the Phase I/II BRUIN study (16:24) Chimeric antigen receptor (CAR) T-cell therapy data with axicabtagene ciloleucel and lisocabtagene maraleucel for R/R follicular lymphoma (FL) (18:24) Bispecific antibodies as treatment for R/R FL: mosunetuzumab, epcoritamab, odronextamab and TNB-486 (22:57) Novel treatment approaches for mantle cell lymphoma (MCL): First-line acalabrutinib/rituximab and lisocabtagene maraleucel for R/R disease (32:54) Updated results from studies evaluating loncastuximab tesirine, such as LOTIS-2, and CAR T-cell therapy, such as TRANSFORM and ZUMA-7, for R/R diffuse large B-cell lymphoma (39:29) Ongoing follow-up from pivotal trials of bispecific antibodies for large B-cell lymphomas (46:01) SWOG-S1826: Results from the Phase III trial evaluating nivolumab with doxorubicin/vinblastine/dacarbazine (AVD) versus brentuximab vedotin with AVD for advanced-stage classic Hodgkin lymphoma (51:48) CME information and select publications

Featuring an interview with Dr Jeremy Abramson, including the following topics: Choice of Bruton tyrosine kinase (BTK) inhibitor as first-line therapy for chronic lymphocytic leukemia (CLL) (0:00) Perspectives on the use of chemoimmunotherapy versus BTK inhibitors as front-line treatment for CLL (2:31) Chimeric antigen receptor (CAR) T-cell therapy-associated ICANS (immune effector cell-associated neurotoxicity syndrome) and infectious complications in patients with CLL (6:21) Available data with bispecific antibodies for CLL (9:38) Sequencing CAR T-cell therapy and pirtobrutinib for patients with previously treated CLL (11:09) Integrating bispecific antibodies into community-based practice; strategies for mitigating associated toxicities (14:25) CD20 versus CD19 as a therapeutic target in lymphomas (20:31) First-line treatment selection for patients with mantle cell lymphoma (23:07) Chemotherapy combined with nivolumab or with brentuximab vedotin as initial therapy for Hodgkin lymphoma (30:12) CME information and select publications  

Welcome to Higher Density Living, where we delve into the profound principles that govern the universe. In this episode, Alexander and Jason will discuss Exo-Biospheric Organisms. As humanity continues to expand its knowledge of the cosmos, the search for extraterrestrial life remains one of the most intriguing and significant scientific endeavors. This episode delves into the enigmatic world of EBOs, discussing their potential existence, characteristics, and implications for our understanding of life beyond our planet. This breakthrough went viral in a Reddit social forum.   The interesting part about this is not its artificial construction but the actual similarities of these organisms to the real, natural design found in our biology. Exo-Biospheric Organisms are proposed to be living entities that thrive in the harsh conditions of space, particularly in the upper atmosphere of planets, moons, or even interstellar space. These organisms would need to be highly adaptable and resilient, capable of surviving extreme temperature fluctuations, radiation exposure, and vacuum conditions.   Given the precedence of this internet sensation, EBOs are the latest in the pipeline of multinational government efforts to sustain and slowly proliferate the declassification of extraterrestrials.   Moreover, the discovery of EBOs could raise ethical questions about human exploration and colonization of celestial bodies. Implementing strict planetary protection protocols will be vital to preserve the pristine environments where EBOs might exist and to avoid disrupting potential ecosystems.   Exo-Biospheric Organisms (EBOs) represent a captivating aspect of astrobiology, fueling our curiosity about life beyond our planet. While their existence remains speculative, the pursuit of discovering these enigmatic organisms pushes the boundaries of our understanding of life's adaptability and the potential for extraterrestrial life. As technology advances and our knowledge of the cosmos expands, the quest to unveil the mysteries of EBOs becomes an integral part of the ongoing search for life beyond Earth.   The discussion then turns to EBOs, organisms believed to exist outside our biosphere that have captured the public imagination. The episode draws parallels between the design of religion and EBOs, highlighting how both resonate with individuals on a spiritual level. The hosts explore the environmental impact of humans versus EBOs and discuss the benefits of copper in human and EBO biology, suggesting artificial intelligence may play a role in EBOs' creation.   While urging a healthy dose of skepticism, we criticize the U.S. military's secrecy around UFOs and argue that independent research is needed to discern truth from misinformation. Ultimately, we argue that the objective of life is to nurture and perfect evolution as close to nature as possible. They advocate for a state of "apotheosis" where we become one with nature.   Let us join Alexander and Jason as discuss Extraterrestrial Organisms.   Please Support our sponsor TARTLE.CO. It is the only marketplace in the world that provides profit to you. Your personal data will serve for helpful causes. Unlocking human understanding through sharing of data and information. www.higherdensityliving.com

What do you get when an alligator falls in love with a raccoon? A vile atrocious unsightly mess... named the Coonigator! Or not, because Mother Nature is a bigot and does not approve of inter-species romance! Along the way we will educate you on just why natural selection prevents the formation of hybrid monstrosities, why it is never a good idea to hug a raccoon, why possums are terrifying, and just why this cute lil cryptid enjoys bananas so much. There is hardly any info on it, so we try to fill in the holes with bananas! Nope, that was not an innuendo! ...

Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments worldwide. Aina and colleagues assessed the safety and activity of ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma. https://pubmed.ncbi.nlm.nih.gov/37414060/ ALSO AS VIDEO ON https://youtu.be/Ymgg22roWGU CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

27 Jun 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company's lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial.

在過去十年中，利用個體的免疫反應應用於癌症治療的理念從理論轉化為現實。使用患者自身的免疫細胞製造的Chimeric antigen receptor (CAR) T-cell 療法對某些侵略性的白血病和血液癌症產生了轉變性的影響。在某些情況下，甚至可以讓經過多種治療後癌症復發的患者痊癒。 生技來一刻邀請到在業界從事CAR T-cell療法開發的張德寬博士帶我們科普CAR T-cell的起源，以及深入簡出地剖析這個技術的現今挑戰以及令人期待的未來走向。 除此之外，德寬也分享自己從台灣博班畢業，來到波士頓擔任博後，以及尋找到業界工作的奮鬥經歷。期間，他一一化解語言、身分、研究方向轉換等不同的挑戰，也將在這集中分享他的心路歷程。 無論你是對細胞療法、台灣博士來美國求職，或是在不同業界工作部門間轉換有興趣，都不要錯過這集乾貨滿滿的podcast!   生技來一刻感謝國科會與駐波士頓辦事處科技組贊助我們製作節目。我們也歡迎聽眾小額捐款生技來一刻，您的支持能幫助我們製作更優質的節目。   BTBA Facebook 專頁：https://www.facebook.com/btbatw 

We welcome the 2023 SLAS Graduate Education Fellowship Grant recipient Samuel G. Berryman, Ph.D. candidate in the Department of Mechanical Engineering from the University of British Columbia (Vancouver, BC, Canada), as our guest.The SLAS grant will support Berryman's research in developing and designing technologies for studying Chimeric antigen receptor (CAR)-T cells, a cell type used for a novel form of cancer therapy.Listen as Berryman shares his research goals and how he thought outside the box to fill the room for his SLAS2023 student presentation.  The SLAS Graduate Education Fellowship Grant directly supports outstanding students pursuing graduate degrees related to life sciences R&D. This program helps realize a fundamental tenet of SLAS's mission: to advance the fields of laboratory science and technology by nurturing the next generation of professional scientists. For more information on SLAS awards and grants, visit https://www.slas.org/careers/awards-and-grants/slas-graduate-education-fellowship-grant/.Stay connected with SLASOnline at www.slas.orgFacebookTwitter @SLAS_OrgLinkedInInstagram @slas_orgYouTubeAbout SLASSLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.  For more information about SLAS, visit www.slas.org.Upcoming SLAS Events: SLAS 2023 Microscales Innovation in Life Sciences Symposium September 14-15, 2023 La Jolla, CA, USA SLAS 2023 Sample Management Symposium October 12-13, 2023 Washington, D.C., USA SLAS 2023 Data Sciences and AI Symposium November 14-15, 2023 Basel, Switzerland SLAS2024 International Conference and Exhibition February 3-7, 2024 Boston, MA, USA

Chimeric Therapeutics (ASX: CHM) managing director and chief executive office Jennifer Chow joins Small Caps to discuss the latest news in the development of its CAR-T therapy CHM 2101. Ms Chow says the cell therapy company received positive feedback from a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) in the lead up to a phase 1A study of the drug in treating gastrointestinal and neuroendocrine tumours. The FDA's responses provide a clear path to an IND submission for CHM 2101. Chimeric is also evaluating another novel CAR-T therapy, CHM 1101, to treat recurrent or progressive glioblastoma (brain cancer). Articles:https://smallcaps.com.au/chimeric-therapeutics-reveals-positive-pre-ind-us-fda-chm-2101/https://smallcaps.com.au/chimeric-therapeutics-doses-final-cohort-brain-cancer-clinical-trial-advances-chm-2101-candidate/ For more information on Chimeric Therapeutics:https://smallcaps.com.au/stocks/CHM/See omnystudio.com/listener for privacy information.

Discusses chimeric research, why it is important to scientific progress, and current recommendations for addressing the ethical and policy issues raised by chimeric research.Our guest is Josephine Johnston, LLB, MBHL who is the Director of Research and a Research Scholar at The Hastings Center, and a Lecturer at The University of Otago's Bioethics Centre. Her research addresses ethical, legal, and policy issues in medicine and science, with a focus on emerging biotechnologies in human reproduction and genetics.Additional Resources:· Research report discussed in this podcast: https://www.thehastingscenter.org/centerreports/clarifying-the-ethics-and-oversight-of-chimeric-research/· The National Academies guidelines for human embryonic stem cell research: https://www.nationalacademies.org/our-work/guidelines-for-human-embryonic-stem-cell-research· The National Academies consensus report on the emerging field of human neural organoids, transplants, and chimeras: https://www.nationalacademies.org/our-work/ethical-legal-and-regulatory-issues-associated-with-neural-chimeras-and-organoids· The International Society for Stem Cell Research guidelines for stem cell research and clinical translation: https://www.isscr.org/guidelines· CITI Program provides an online module on human-animal chimera research: https://about.citiprogram.org/course/technology-ethics-and-regulations/

22 Mar 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on the company's trials.

Featuring perspectives from Dr Matthew Lunning, including the following topics: •      Potential role of polatuzumab vedotin/R-CHP in therapy for previously untreated diffuse large B-cell lymphoma (DLBCL) (00:00) •      Association between metabolic tumor volume and clinical outcomes with loncastuximab tesirine in the LOTIS-2 trial and axicabtagene ciloleucel in the ZUMA-7 trial (10:54) •      Chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas: Activity, tolerability and patient selection (22:16) •      Efficacy of and durable complete responses with bispecific antibodies in patients with DLBCL (36:48) •      Five-year results and overall survival update from the Phase III AUGMENT study evaluating rituximab and lenalidomide (R2) versus rituximab and placebo for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (42:44) •      Activity and safety of tazemetostat in combination with (R2) in patients with R/R follicular lymphoma (FL) (44:52) •      Long-term clinical outcomes with CAR T-cell therapies for patients with R/R FL (46:50) •      Available data with and ongoing studies of bispecific antibodies for R/R FL (50:23) •      Design and outcomes of the SHINE and TRIANGLE studies in mantle cell lymphoma (MCL); evolving role of transplantation for MCL (1:00:38) •      Real-time monitoring of minimal residual disease in patients receiving acalabrutinib with (R2) for treatment-naïve MCL (1:13:29) •      Assessment of durable responses after brexucabtagene autoleucel for R/R MCL in the ZUMA-2 trial (1:15:29) •      High complete response rates with glofitamab for patients with heavily pretreated MCL (1:19:00) •      Nivolumab with ICE (ifosfamide/carboplatin/etoposide) as first salvage therapy for patients with high-risk R/R Hodgkin lymphoma (1:21:04) •      Efficacy and safety of camidanlumab tesirine in patients with R/R classical Hodgkin lymphoma (1:23:07) •      Importance of brain-to-vein time in patients receiving CAR T-cell therapy (1:25:37) CME information and select publications

Not often do you hear frighful information in the fringe world but also presents solutions to something that seems out of our control. On this episode we talk with Enoch about some research on what was really in this supposed ''bat virus'' and how thew powers that be spread it on a global scale. We also discuss what to do to filter out the "virus". We are not asking you to do this instead of other medical practices, we are just presenting research that might be able to help even in future planned pandemics. We also talk about how 5G tech and the WAxxine might be a trojan horse for a zombie like reaction.    This one is a wild ride folks! Don't forget to spread the fire! Chimeric payload engineering

Following up on our last Overview episode, we get to all the stuff we couldn't fit in to the previous episode. Including a discussion of the three Super Deformed Shorts, our favorite characters, chimeric animal designs, and more. We also lay some hints at another bonus surprise coming before we finally arrive at Book Three.    This episode was recorded on Dec. 27th, 2022.    Email the show at tnebendingtheelements@gmail.com 

Nonhuman Animals Containing Human Cells: Ethics and Oversight Karen Maschke, PhD, Research Scholar at The Hastings Center Website | Twitter @hastingscenter This presentation focuses on ethical and oversight issues as they relate to the insertion of human cells into nonhuman animals, e.g., “chimeric research.” Abstract Research involving the insertion of human cells into nonhuman animals at various stage of development – referred to here as chimeric research – has helped scientists learn how human cells behave in a living environment. Advances in human stem cell science and gene editing are enabling scientists to more extensively and precisely insert human cells into nonhuman animals at any stage of development. Scientists have conducted in vitro experiments with chimeric embryos and in vivo studies that create chimeric animals. The goals of these studies include developing more accurate models of human diseases, creating inexpensive sources of human eggs and embryos for research, and developing sources of tissues and organs suitable for transplantation into humans. Yet concerns have been raised that by biologically altering nonhuman animals with human cells – particularly at an early stage of the chimeric animal's development – scientists may end up changing them in morally relevant ways, especially if the chimeric animals exhibit “humanlike” behaviors or capacities that they previously lacked. An NIH-funded interdisciplinary research project of The Hastings Center and Case Western Reserve University examined the ethical, oversight, and policy issues regarding research that involves the transfer of human embryonic or induced pluripotent cells, or cells derived directly from them, into nonhuman animals or nonhuman animal embryos. This presentation highlights three of the project's recommendations: scientists, journalists, bioethicists and others writing about chimeric research should use precise and accessible language that clarifies rather than obscures the ethical issues at stake; animal welfare is a primary ethical issue and should be a focus of ethical and policy analysis as well as the governance of oversight of chimeric research; and enhanced communication between institutional committees involved in oversight of chimeric research is needed, as well as a mechanism for a national discussion amongst those in oversight of these studies. Related links: Clarifying the Ethics and Oversight of Chimeric Research, Josephine Johnston, Insoo Hyun, Carolyn P. Neuhaus, Karen J. Maschke, et. al., 2022 Composite Animals: Then and Now, Amy Hinterberger, 2022 Human, Nonhuman, and Chimeric Research: Considering Old Issues with New Research, Jeff Sebo, Brendan Parent, 2022 Threats to Benefits: Assessing Knowledge Production in Nonhuman Models of Human Neuropsychiatric Disorders, Carolyn P. Neuhaus, 2022 Moral Status and the Oversight of Research Involving Chimeric Animals, Patricia Marshall, Kaitlynn P. Craig, Insoo Hyun, 2022 A Conversation with Chimeric Animal Researchers, Kaitlynn P. Craig, 2022 How Chimeric Animal Research Impacts Animal Welfare: A Conversation with Animal Welfare Experts, Kaitlynn P. Craig, 2022 Speaker Bio Karen J. Maschke, PhD is a Research Scholar at The Hastings Center and the editor of the Center's journal, Ethics & Human Research. As a researcher with training in political science and bioethics, she focuses on policy and ethical issues related to the introduction, use, regulation, and oversight of new biomedical technologies. She recently completed two projects: the NIH-funded project, “Actionable Ethics Oversight for Human-Animal Chimera Research” (co-Principal Investigator) and the NSF-funded project, “Public Deliberation on Gene Editing in the Wild” (co-Investigator). She is currently the lead co-Principal Investigator of the NIH-funded project, “Informing Ethical Translation of Xenotransplantation Clinical Trials.” She is interviewed frequently by the media, appearing in AP, New York Times, Wall Street Journal, NPR, Washington Post, Kaiser Health, STAT News, Reuters, and Bloomberg Law. Her recent book (co-authored with Michael K. Gusmano), is Debating Modern Medical Technologies: The Politics of Safety, Effectiveness, and Patient Access (Praeger, 2018). GES Colloquium (GES 591-002) is jointly taught by Drs. Jen Baltzegar and Dawn Rodriguez-Ward, who you may contact with any class-specific questions. Colloquium will generally be live-streamed via Zoom, with monthly in-person meetings in the 1911 Building, room 129. Please subscribe to the GES newsletter and Twitter for updates . Genetic Engineering and Society Center GES Colloquium - Tuesdays 12-1PM (via Zoom) NC State University | http://go.ncsu.edu/ges-colloquium GES Mediasite - See videos, full abstracts, speaker bios, and slides https://go.ncsu.edu/ges-mediasite Twitter - https://twitter.com/GESCenterNCSU GES Center - Integrating scientific knowledge & diverse public values in shaping the futures of biotechnology. Find out more at https://ges-center-lectures-ncsu.pinecast.co

Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX Recorded on December 16, 2022 Chimeric antigen receptor (CAR) T-cell therapy has generated impressive results in hematologic malignancies, with many drugs still in clinical trials. In this episode, Dr. Sattva S. Neelapu from MD Anderson Cancer Center, joins us to discuss updates on CAR T-cell therapy from the 2022 American Society of Hematology (ASH) Annual Meeting. Dr. Neelapu also provides a high-level overview of how CAR T-cell therapy works, including the manufacturing process, and discusses the risk of recurrence following therapy, risk for patients in the era of COVID-19, secondary cancers, associated costs, roadblocks to therapy, and why early referral matters. Tune in to this informative podcast episode to learn more! This podcast episode is supported by Allogene Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Janssen Oncology & Legend Biotech, Kite, A Gilead Company and Novartis Oncology.

Chris and Crystal review the relic from the future, The Chimeric Herbarium by the Zoetica Ebb, which explores the strange, exotic, and rather deadly, plants that exist on a world many light years away. The Chimeric Herbarium is a coffee table art book collecting the work of Zoetica Ebb, which, while being a collection of her art, is also filled with details and discussions of alien flora that would not be out of place in fantasy and sci-fi RPGs.   Episode Corrections: The dresses modelled by Ulorin Vex that feature Zoetica's designs were not made by PlastikWrap, but rather facilitated by Adriana Fulop, owner of Plastik Wrap. The digital art was created in conjunction with Peachthief.   Chris also briefly reviews the Mörk Borg compatible grim-dark sci-fi RPG, Vast Grimm, a suitable candidate for using the ideas presented in the Chimeric Herbarium. Be sure to check us out on Facebook or through our Discord server https://discord.gg/GGuRKAn. To stay up to date, subscribe through iTunes or Spotify!  Find more information at choice.crd.co and consider donating to abortion funds. Look to abortion fund leaders for guidance and please speak up, take care, and spread the word.  shoutyourabortion.com - a campaign to normalize abortion https://www.bustle.com/politics/abortion-funds-states-trigger-bans-donate - a list of abortion funds in states where it is no longer protected https://secure.actblue.com/donate/supportabortionfunds - where you can donate money to be split between 80+ abortion funds           Links For This Episode:   ICRC Ukraine: https://www.icrc.org/en/where-we-work/europe-central-asia/ukraine Darker Days Linktree: https://linktr.ee/DarkerDaysRadio Darker Days Discord: https://discord.gg/GGuRKAn Full Metal RPG: https://fullmetalrpg.podbean.com/ The Realm of Fire: https://realmoffire.podbean.com/     Want more spooky stories and sinister plot hooks? Check out Secret Frequency Files 2:

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.10.515982v1?rss=1 Authors: Wang, W., Zhang, X., Zhao, N., Xu, Z.-H., Jin, K., Jin, Z.-B. Abstract: Chimeric RNAs have been found in both cancer and healthy human cells. They have regulatory effects on human stem/progenitor cell differentiation, stemness maintenance and central nervous system (CNS) development. However, their physiological functions in the retinal development remain unknown. Based on the human embryonic stem cells (hESC)-derived retinal organoids (ROs) spanning from day 0 to day 120, we present the expression atlas of chimeric RNAs throughout the developing ROs. We confirmed the existence of some common chimeric RNAs and also discovered many novel chimeric RNAs during retinal development. We focused on CTNNBIP1-CLSTN1 (CTCL) whose downregulation causes precocious neuronal differentiation and a marked reduction of neural progenitors in human cerebral organoids. Our study found that CTCL also plays a key role in human retinogenesis, CTCL loss-of-function obstructed RO differentiation but prompted the retinal pigment epithelial (RPE) differentiation. Together, this work provides a landscape of chimeric RNAs and reveals evidence for their crucial roles in human retina development. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

04 Nov 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses the company's new agreement with Case Western Reserve University.

After a brain transplant of reprogrammed human cells, the animals can for the first time recapitulate some neuronal changes seen in people with fragile X syndrome. The post Fragile X neurons develop atypically in chimeric mice appeared first on Spectrum | Autism Research News.

After a brain transplant of reprogrammed human cells, the animals can for the first time recapitulate some neuronal changes seen in people with fragile X syndrome.

After a brain transplant of reprogrammed human cells, the animals can for the first time recapitulate some neuronal changes seen in people with fragile X syndrome.

Chimeric Therapeutics CEO Jennifer Chow speaks with Proactive at the ASX Small and Mid-Cap Conference September 2022. Chimeric Therapeutics is a clinical stage cell therapy company. It believes that cellular therapies have the promise to cure cancer rather than just delay its progression. The company focuses on discovery, development and commercialisation of the most innovative cell therapies. #ChimericTherapeutics #cancertherapy #asx #proactiveaustralia

It looks like the Tasmanian tiger's turn to enter the debate on whether or not scientists can or should bring species back from extinction. Colossal Biosciences & Laboratories, announced yesterday that it plans to resurrect the extinct marsupial. http://www.troubledminds.org Support The Show! https://rokfin.com/creator/troubledminds https://troubledfans.com https://patreon.com/troubledminds#aliens #conspiracy #paranormalRadio Schedule Mon-Tues-Wed-Thurs 7-9pst - https://fringe.fm/iTunes - https://apple.co/2zZ4hx6Spotify - https://spoti.fi/2UgyzqMStitcher - https://bit.ly/2UfAiMXTuneIn - https://bit.ly/2FZOErSTwitter - https://bit.ly/2CYB71UFollow Algo Rhythm -- https://bit.ly/3uq7yRYFollow Apoc -- https://bit.ly/3DRCUEjFollow Ash -- https://bit.ly/3CUTe4ZFollow Daryl -- https://bit.ly/3GHyIaNFollow James -- https://bit.ly/3kSiTEYFollow Jennifer -- https://bit.ly/3BVLyCMFollow Joseph -- https://bit.ly/3pNjbzb Matt's Book -- https://bit.ly/3x68r2d -- code for free book WY78YFollow Nightstocker -- https://bit.ly/3mFGGtxRobert's Book -- https://amzn.to/3GEsFUKFollow TamBam -- https://bit.ly/3LIQkFw-------------------------------------------------Genetics startup wants to bring the Tasmanian tiger back | Popular Sciencehttps://www.popsci.com/environment/genetics-startup-tasmanian-tiger/life-cycle-rev.png (1200×1200)https://www.cnet.com/a/img/resize/6b701f615656e6d5401b467c4ed2f564284ff7a3/hub/2022/08/16/fd8f8fbb-014e-4046-841d-e441548962c5/life-cycle-rev.png?auto=webp&width=1200Inside the Plan to Resurrect Australia's Extinct Tasmanian Tiger - CNEThttps://www.cnet.com/science/biology/features/inside-the-plan-to-resurrect-australias-extinct-tasmanian-tiger/Once Thought Extinct, the Tasmanian Tiger May Still Be Prowling the Planet | HowStuffWorkshttps://animals.howstuffworks.com/extinct-animals/tasmanian-tiger.htmThylacine - Wikipediahttps://en.wikipedia.org/wiki/Thylacine10 Facts About the Tasmanian Tigerhttps://www.thoughtco.com/facts-about-the-tasmanian-tiger-1093338Woolly mammoths could walk the Earth again by 2027 if CRISPR startup succeeds - CNEThttps://www.cnet.com/science/woolly-mammoths-could-walk-the-earth-again-by-2027-if-crispr-startup-succeeds/The Real Reason The Tasmanian Tiger Went Extincthttps://www.grunge.com/620861/the-real-reason-the-tasmanian-tiger-went-extinct/Tasmanian Tiger sightings: Man releases photos of ‘living' thylacine family | news.com.au — Australia's leading news sitehttps://www.news.com.au/technology/science/animals/proof-tasmanian-tiger-still-exists-with-new-photos-of-family-released/news-story/01b96a8c4f39054a2dc3fd92c9bf5c35What is a chimera? | New Scientisthttps://www.newscientist.com/question/what-is-a-chimera/Understanding 'Chimeras' And How They Might Save Liveshttps://uproxx.com/life/what-are-chimeras-genetically-engineered-animal-hybrids-explainer/What Is a Human Chimera and How Does It Happen?https://www.insider.com/what-is-a-human-chimera-and-how-does-it-happen-2017-11Can An Organ Transplant Change A Recipient's Personality? Cell Memory Theory Affirms 'Yes'https://www.medicaldaily.com/can-organ-transplant-change-recipients-personality-cell-memory-theory-affirms-yes-247498Personality changes following heart transplantation: The role of cellular memory - PubMedhttps://pubmed.ncbi.nlm.nih.gov/31739081/Cellular memory | Psychology Wiki | Fandomhttps://psychology.fandom.com/wiki/Cellular_memoryBody memory - Wikipediahttps://en.wikipedia.org/wiki/Body_memoryThe Science of Cellular Memories · Dr. Alexhttps://www.dralexanderloyd.com/blog/the-science-of-cellular-memoriesHuman-Pig Hybrid Created in the Lab—Here Are the Factshttps://archive.ph/BPfOwHuman-Pig Hybrid Created in the Lab - Scientists hope the chimera embryos represent key steps toward life-saving lab-grown organs. : interestingasfuckhttps://www.reddit.com/r/interestingasfuck/comments/mj8ong/humanpig_hybrid_created_in_the_lab_scientists/

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView's “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don't miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView's “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don't miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView's “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don't miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView's “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don't miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView's “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don't miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView's “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don't miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.

0:00 Intro 2:25 Edible Oils Crisis 15:05 Zombies 38:05 Gonzalo Lira 43:55 Russia For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Peek into the future of gene therapy and its capacity to treat – maybe eliminate – genetic diseases like cancers and hemophilia. Plus, the potential to reverse the effects of aging. It's a future scientists have been working toward for years: How to treat complex health  problems with gene therapy. And researchers have been making progress. Diagnoses once thought to be fatal are now being looked at in a new light.This is a welcome sight for physicians, caregivers, and – most of all – for the patients living with these genetic diseases. One disease that's impacting lives worldwide is cancer. Nearly 40% of the world's population will be diagnosed with it at some stage of life.Typically, cancer treatment takes three forms: chemotherapy, surgery, or radiation therapy. Targeted drug therapies also exist, which work by identifying and attacking cancer cells individually.But the treatment that many believe has the most potential is immunotherapy.Immunotherapy uses a patient's immune system to target and destroy cancerous tumors. And a specific type of immunotherapy known as Chimeric antigen receptor (or CAR) T-cell therapy has particular promise.Over the last few years, progress with this new class of gene-based treatment has accelerated.CAR T-cell Therapy is when a patient's own immune cells – the white blood cells called T cells – are genetically altered to target and attack a specific cancer within the body. These cells are first removed from the patient's blood. Their genes are then altered to produce proteins called CARs, which allow the T cell to better recognize – and attack – specific cancer cells. When the altered immune cells are reintroduced into the patient's bloodstream, these proteins latch onto both healthy and cancerous cells, destroying the cancerous cells while leaving the healthy cells unharmed.CAR T-cell Therapy has the ability to revolutionize cancer treatment and prevent relapse, as  these cells can potentially continue to attack cancerous cells in a patient's body for years. But it's not a solution for everyone. Only about 40% of patients have long-term responses.But if this therapy achieves what scientists believe it can, chemotherapy could be a thing of the past, and when it comes to the future of gene therapy and genetic diseases, there's reason for optimism.For more education on gene therapy, visit www.genetherapynetwork.com.

Chimeric antigen receptor (CAR) T cell immunotherapies hold great promise for cancer treatment, but they are not very effective against solid tumors. Niki Spahich from The Scientist's Creative Services team spoke with Katie McKenna, postdoctoral fellow in the laboratory of Malcolm Brenner at the Center for Cell and Gene Therapy at Baylor College of Medicine, about her work developing a combination CAR T cell immunotherapy and oncolytic virotherapy to treat solid tumors. LabTalk is a special edition podcast produced by The Scientist's Creative Services Team, where we explore topics at the leading edge of innovative research. This episode was sponsored by IsoPlexis.

Tracklist 00:15 | Helios - Soft Collared Neck 03:33 | OK Go - The Great Fire 05:24 | Karma Fields - Edge Of The World 06:50 | (vs Stonebank - Dark) 08:20 | Puppet & The Eden Project - The Fire 12:32 | Dirtyphonics & Sullivan King - Vantablack 13:23 | Virtual Riot - Hysteria 14:01 | Pixel Terror & JayKode - Dystopia 14:27 | Gammer - Brostep Strikes Back (Beatplant Christmas Edit) 15:37 | Kayzo & RIOT - Wake Up 18:12 | London Elektricity - Build A Better World (feat. Emer Dineen) 20:02 | slphr. & aeris - invain 22:37 | Mazare & Essenger - Berserker 25:06 | Protostar - No Turning Back 27:39 | RIOT - Blackwater 31:34 | (vs Pegboard Nerds - Supersonic (feat. Chimeric)) 32:17 | Pegboard Nerds - Supersonic (feat. Chimeric) 34:06 | Koven - Give You Up 36:08 | Culprate & Au5 - Impulse 38:02 | Eptic - Beyond The Stars 39:57 | SLUMBERJACK & Ekali - Closure 41:28 | Infected Mushroom - Spitfire 43:33 | Steve Aoki, Deorro, MAKJ, & Max Styler - Shakalaka 45:01 | (vs Xilent - Particles) 45:27 | Xilent - Particles 46:44 | Sullivan King - I'll Fight Back 48:35 | Xilent - Discarded 50:05 | Code: Pandorum - The Lovecraftian Horrors 52:09 | Frequent - Dream Recall (feat. Alexander Panos) 1:03:31 | Clint Mansell - Lux Aeterna 1:05:45 | Justin Hawkes - Ryan 1:11:04 | Blonde Redhead - For The Damaged Coda 1:13:34 | CloudNone - Urban Foxes 1:15:49 | (vs Pixel Terror - Arctica) 1:17:19 | Just A Gent - Time Voyage (feat. Hauskey) 1:19:34 | Au5 - Eden (feat. Danyka Nadeau) 1:22:22 | Xilent - Shadow Of You 1:24:06 | 7 Minutes Dead - The Divide 1:28:19 | Knife Party vs Au5 - Ghost Train vs Beautiful Sky (feat. Daniel Hanson) 1:29:54 | Au5 - Beautiful Sky (feat. Daniel Hanson) 1:33:27 | Porter Robinson - Goodbye To A World 1:37:13 | (vs San Holo & Duskus - forever free) 1:38:46 | Sullivan King & Grabbitz - Crazy As You 1:41:23 | soupandreas & inverness - Tumbling Down 1:42:40 | LVTHER - Some Kind Of Magic (feat. MYZICA) 1:45:48 | Pokemon XY - Gate Theme (Strobe Remix) 1:47:13 | Tears For Fears - Head Over Heels 1:51:15 | Grant - Wishes (feat. McCall) 1:53:13 | Brandyn Burnette & dwilly - Hands Down (feat. Kayo Genesis) 1:55:26 | Jaron - Catch 1:56:16 | AERØHEAD - Lost Memories 1:58:52 | Grant - Where Will We Go (Acoustic)

Tracklist 00:15 | Darren Styles - Switch (Extended Mix) 03:13 | Stonebank - The Government 04:00 | Gammer - THE DROP (4B x NvrLeft Remix) 05:07 | Pegboard Nerds - Supersonic (feat. Chimeric) 08:33 | Scooter - Rebel Yell [Memories] 12:06 | S3RL - Cherry Pop (feat. Gl!tch) 13:15 | (vs Sullivan King - I'll Fight Back) 13:48 | Jan Level - WORLD PEACE [Memories] 14:39 | DV-i - Human Index (feat. K.K. Togashi) 17:58 | Manuel - Gas Gas Gas 22:25 | S3RL - BFF (ID x ID Remix) [Developing] 23:34 | Crankdat - Who I Am (ID Bootleg) [Developing] 25:15 | sakurabust - skyshifter vip

What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine? The post Part 3: Chimeric vaccines combine strengths of each antigen to provide better coverage appeared first on Pig Health Today.